SIM
SPRO icon

Spark Investment Management’s Spero Therapeutics SPRO Stock Holding History

Spark Investment Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-23,600
Closed -$145K – 713
2018
Q4 		$145K Buy
+23,600
New +$191K 0.01% 531

Other funds holding SPRO

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Spark Investment Management's SPRO Position: Q1 2019 in Review

Spark Investment Management sold out of Spero Therapeutics (SPRO) in Q1 2019, closing a stake of 23,600 shares — an estimated $145K sold.

Spark Investment Management first reported a position in SPRO in Q4 2018 and held it in 1 quarter. The position peaked at $145K in Q4 2018. 55 funds tracked by Wall St. Rank hold SPRO as of Q1 2019.

  • Spark Investment Management reported no remaining Spero Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Spark Investment Management sold 23,600 Spero Therapeutics shares in Q1 2019, an estimated $145K.
  • Spark Investment Management first reported a position in Spero Therapeutics in Q4 2018 and held it in 1 quarter.
  • Spark Investment Management's Spero Therapeutics position peaked at $145K in Q4 2018.
  • 55 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2019.

Based on Spark Investment Management's 13F filing for Q1 2019, filed 7 May 2019.